ArticleCancer cell international2025
Construction of a lipid metabolism-based prognostic gene signature in cervical squamous cell carcinoma and validation of LIPG's oncogenic role.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomics, identification, and testing of manganese metabolism-related genes in cervical squamous cell carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCervical cancer, in which cervical squamous cell carcinoma (CSCC) accounts for 60-70% of cases, has a poor prognosis and poses a significant health threat to global patients. Lipid metabolism reprogramming is a key driver of tumor progression and tumor microenvironment (TME) regulation, making it a promising target for improving the efficacy of immunotherapy. This study aimed to construct a lipid metabolism prognostic signature (LMPS) in CSCC and identify key genes involved in tumor progression.
methodsThrough RNA-sequencing and clinical data from TCGA and GTEx databases, we identified differentially expressed lipid metabolism-related genes (DLMGs) and constructed the LMPS using machine learning algorithms. Next, the value of the LMPS was validated using the HTMCP database and the GEO database. Furthermore, the relationship between the LMPS and the TME was analyzed, including immune cell infiltration, immune checkpoint gene expression, and drug sensitivity. The key gene lipase G (LIPG) was identified through machine learning methods and validated through cellular and molecular biology experiments.
resultsA total of 60 DLMGs were identified, with 9 DLMGs showing prognostic value. The LMPS was constructed using 6 genes (ACOT4, PLA2G2D, GAL3ST1, ALOX12B, PLA2G3, and LIPG), which effectively predicted patients' survival (AUC: 0.76, 0.75, 0.68 at 1, 3, 5 years, respectively). High LMPS was correlated with an immune-suppressive TME, reduced immune cell infiltration, lower human leukocyte antigen (HLA) and immune checkpoint gene expression, and higher IC50 values for common chemotherapy drugs. LIPG was identified as a key gene, showing higher expression in advanced cancer stages. As revealed by functional experiments, LIPG promoted lipid accumulation and phosphatidylcholine (PC) hydrolysis in CSCC cells. Additionally, LIPG facilitated tumor progression through activation of the MAPK-p38 signaling pathway.
conclusionsThe LMPS was a valuable prognostic tool and was correlated with the TME and drug sensitivity. LIPG was a key regulator of lipid metabolism and facilitated CSCC development by hydrolyzing PC into lysophosphatidylcholine (LPC) and activating the MAPK-p38 signaling pathway. These findings may highlight the potential of targeting lipid metabolism for therapeutic intervention in CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.